

CARE Checklist of information to include when writing a case report





Topic	Item	Checklist item description	Reported on Line
Title	1	The diagnosis or intervention of primary focus followed by the words "case report"	<u>Line1</u>
Key Words 2		2 to 5 key words that identify diagnoses or interventions in this case report, including "case report"	<u>Line28</u>
Abstract (no references)	3a	Introduction: What is unique about this case and what does it add to the scientific literature?	<u>Line13-19</u>
	3b	Main symptoms and/or important clinical findings	<u>Line18-19</u>
	3c	The main diagnoses, therapeutic interventions, and outcomes	<u>Line19-22</u>
	3d	Conclusion—What is the main "take-away" lesson(s) from this case?	<u>Line25, 26</u>
Introduction	4	One or two paragraphs summarizing why this case is unique (may include references)	<u>Line30-40</u>
Patient Information	5a	De-identified patient specific information	<u>Line42-89</u>
	5b	Primary concerns and symptoms of the patient	<u>Line44-47</u>
	5c N	Medical, family, and psycho-social history including relevant genetic information	<u>Line43-44</u>
	5 d	Relevant past interventions with outcomes	. <u>Line47-49</u>
Clinical Findings	6	Describe significant physical examination (PE) and important clinical findings	<u>Line49-71</u>
Timeline	7	Historical and current information from this episode of care organized as a timeline	Line80 fig.4
Diagnostic Assessment	8a	Diagnostic testing (such as PE, laboratory testing, imaging, surveys)	<u>Line50-78</u>
	8b	Diagnostic challenges (such as access to testing, financial, or cultural)	<u>Line78</u>
	8c	Diagnosis (including other diagnoses considered)	<u>Lin70-78</u>
	8d	Prognosis (such as staging in oncology) where applicable	. <u>Line72-78</u>
Therapeutic Intervention	9a ¯	Types of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care)	. <u>Line70-71</u>
	9b	Administration of therapeutic intervention (such as dosage, strength, duration)	. <u>Line70-71</u>
	9c (Changes in therapeutic intervention (with rationale)	. N,shown in response
Follow-up and Outcomes	10a	Clinician and patient-assessed outcomes (if available)	N,shown in response
	10b	Important follow-up diagnostic and other test results	<u>Line79-81</u>
	10c	Intervention adherence and tolerability (How was this assessed?)	N,shown in response
	10d	Adverse and unanticipated events	<u>Line79-81</u>
Discussion	11a ,	A scientific discussion of the strengths AND limitations associated with this case report	<u>Line134-138</u>
	11b	Discussion of the relevant medical literature with references	. <u>Line88-89,90-92,129-131</u>
	11c	The scientific rationale for any conclusions (including assessment of possible causes)	<u>Line102-120</u>
	11d	The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion	<u>Line142-149</u>
Patient Perspective	12	The patient should share their perspective in one to two paragraphs on the treatment(s) they received . \dots	<u>Line138-140</u>
Informed Consent	13	Did the patient give informed consent? Please provide if requested	Yes 🗹 No 🗌

Article information: http://dx.doi.org/10.21037/apm-20-321

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version.